pirfenidone has been researched along with Conjunctival Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baynes, R; Khattab, A; Mowat, F; Oh, A; Salmon, B; Westermeyer, HD; Yeatts, J | 1 |
| Lin, X; Sun, G; Wu, K; Yu, M; Zhong, H | 1 |
1 trial(s) available for pirfenidone and Conjunctival Diseases
| Article | Year |
|---|---|
Safety and efficacy of topically applied 0.5% and 1% pirfenidone in a canine model of subconjunctival fibrosis.
Topics: Administration, Topical; Animals; Aqueous Humor; Conjunctival Diseases; Disease Models, Animal; Dogs; Drug Implants; Female; Fibrosis; Pyridones; Random Allocation | 2019 |
1 other study(ies) available for pirfenidone and Conjunctival Diseases
| Article | Year |
|---|---|
Evaluation of pirfenidone as a new postoperative antiscarring agent in experimental glaucoma surgery.
Topics: Actins; Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Movement; Cell Proliferation; Cicatrix; Collagen; Conjunctival Diseases; Disease Models, Animal; Drug Evaluation; Endothelium, Corneal; Glaucoma; Intraocular Pressure; Mitomycin; Ophthalmic Solutions; Postoperative Complications; Proliferating Cell Nuclear Antigen; Pyridones; Rabbits; Trabeculectomy; Tumor Necrosis Factor-alpha | 2011 |